KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

2024-513285-19-00 Protocol KO-2806-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 14 Mar 2025 · Status Ongoing, recruiting · 4 EU/EEA countries · 16 sites · Protocol KO-2806-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 300
Countries 4
Sites 16

Pancreatic Ductal Adeno Carcinoma

Key facts

Sponsor
Kura Oncology Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 Mar 2025 → ongoing
Decision date (initial)
2025-01-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513285-19-00
ClinicalTrials.gov
NCT06026410

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pancreatic Ductal Adeno Carcinoma

VersionLevelCodeTermSystem organ class
21.1 PT 10061873 Non-small cell lung cancer 100000004864
21.1 LLT 10051971 Pancreatic adenocarcinoma 10029104
21.1 PT 10067946 Renal cell carcinoma 100000004864
21.0 PT 10061451 Colorectal cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Kura Oncology Inc.

Sponsor organisation
Kura Oncology Inc.
Address
4930 Directors Place Suite 500
City
San Diego
Postcode
92121-3848
Country
United States

Scientific contact point

Organisation
Kura Oncology Inc.
Contact name
Kura Medical Information

Public contact point

Organisation
Kura Oncology Inc.
Contact name
Kura Medical Information

Locations

4 EU/EEA countries · 16 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 15 4
Germany Ongoing, recruiting 8 3
Italy Ongoing, recruiting 27 5
Spain Ongoing, recruiting 16 4
Rest of world
United States
234

Investigational sites

France

4 sites · Ongoing, recruiting
Oncopole Claudius Regaud
Oncologie Médicale, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Assistance Publique Hopitaux De Paris
Oncologie Médicale, Num Voie 47 A 83, 47 Boulevard De L Hopital, Paris
Assistance Publique Hopitaux De Paris
Oncologie Médicale, 20 Rue Leblanc, 75015, Paris
Centre Leon Berard
Oncologie Médicale, 28 Rue Laennec, 69008, Lyon

Germany

3 sites · Ongoing, recruiting
Charite Universitaetsmedizin Berlin KöR
Med. Klinik m.S. Hämato-Onkologie, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsklinikum Wuerzburg AöR
Interdisziplinäres Studienzentrum, Josef-Schneider-Strasse 6, Grombuehl, Wuerzburg
Universitaetsklinikum Ulm AöR
Comprehensive Cancer Center Ulm (CCCU) – Early Clinical Trials Unit (ECTU), Albert-Einstein-Allee 23, Eselsberg, Ulm

Italy

5 sites · Ongoing, recruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Ricerca Traslazionale a Servizio dei percorsi oncologici, Via Mariano Semmola 52, 80131, Naples
Centro Ricerche Cliniche Di Verona S.r.l.
Oncology Section, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
SC Oncology, Strada Provinciale 142 Orba Km 3,95, 10060, Candiolo
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Oncology and Haematology, Via Pietro Albertoni 15, 40138, Bologna
Humanitas Mirasole S.p.A.
U.O di Oncologia Medica ed Ematologia, Via Alessandro Manzoni 56, 20089, Rozzano

Spain

4 sites · Ongoing, recruiting
Hospital De La Santa Creu I Sant Pau
Oncology, Calle De San Antonio Maria Claret 167, 08025, Barcelona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-03-14 2025-05-06
Germany 2026-03-23 2026-04-01
Italy 2025-04-04 2025-04-22
Spain 2025-03-28 2025-04-07

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-30 Spain Acceptable
2025-01-30
2025-01-30
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-19 Spain Acceptable
2025-01-30
2025-02-19
3 SUBSTANTIAL MODIFICATION SM-1 2025-02-26 Acceptable 2025-03-21
4 SUBSTANTIAL MODIFICATION SM-2 2025-03-27 Spain Acceptable 2025-04-11
5 SUBSTANTIAL MODIFICATION SM-3 2025-06-10 Spain Acceptable
2025-09-15
2025-09-16
6 NON SUBSTANTIAL MODIFICATION NSM-2 2025-10-10 Spain Acceptable
2025-09-15
2025-10-10
7 NON SUBSTANTIAL MODIFICATION NSM-3 2025-11-17 Spain Acceptable
2025-09-15
2025-11-17
8 SUBSTANTIAL MODIFICATION SM-4 2025-12-04 Spain Acceptable
2026-03-09
2026-03-09
9 SUBSTANTIAL MODIFICATION SM-5 2026-03-17 Acceptable 2026-04-20